◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › J › JNJ

Johnson & Johnson (JNJ) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Pharmaceuticals · DATA UPDATED 2026-08-07

Johnson & Johnson (JNJ) operates in the Pharmaceuticals industry and is headquartered in New Brunswick, United States with about 138,200 employees. Its market capitalization is roughly $651 billion. In the fiscal year ended 2025-12-31, JNJ reported $94.2B in revenue and $26.8B in net income.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.

Interactive charts & full statements → Open the JNJ valuation workbench →

JNJ Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$97.9B	$94.2B	$88.8B	$85.2B	$80.0B	$78.7B	$82.6B	$82.1B	$81.6B	$76.5B	$71.9B	$70.1B	$74.3B	$71.3B	$67.2B	$65.0B	$61.6B	$61.9B	$63.7B	$61.1B	$53.3B
Gross Profit	$69.0B	$68.6B	$61.4B	$58.4B	$55.4B	$55.3B	$54.2B	$54.5B	$54.5B	$51.0B	$50.1B	$48.5B	$51.6B	$49.0B	$45.6B	$44.7B	$42.8B	$43.5B	$45.2B	$43.3B	$38.3B
Gross Margin %	70.5%	72.8%	69.1%	68.6%	69.2%	70.3%	65.6%	66.4%	66.8%	66.7%	69.7%	69.3%	69.4%	68.7%	67.8%	68.7%	69.5%	70.2%	71.0%	71.0%	71.8%
Operating Income (EBIT)	$26.3B	$25.6B	$22.1B	$21.9B	$21.0B	$20.9B	$19.7B	$21.0B	$21.2B	$18.9B	$20.9B	$18.3B	$21.1B	$19.0B	$17.0B	$16.2B	$16.5B	$16.7B	$16.2B	$15.2B	$13.7B
Operating Margin %	26.8%	27.2%	24.9%	25.7%	26.3%	26.6%	23.9%	25.6%	26.0%	24.7%	29.1%	26.1%	28.4%	26.6%	25.3%	24.8%	26.8%	26.9%	25.4%	24.9%	25.7%
Net Income	$21.0B	$26.8B	$14.1B	$35.2B	$17.9B	$20.9B	$14.7B	$15.1B	$15.3B	$1.3B	$16.5B	$15.4B	$16.3B	$13.8B	$10.9B	$9.7B	$13.3B	$12.3B	$12.9B	$10.6B	$11.1B
Net Margin %	21.5%	28.5%	15.8%	41.3%	22.4%	26.5%	17.8%	18.4%	18.8%	1.7%	23.0%	22.0%	22.0%	19.4%	16.1%	14.9%	21.6%	19.8%	20.3%	17.3%	20.7%
EBITDA	$31.9B	$41.1B	$24.8B	$29.3B	$26.6B	$26.8B	$23.9B	$24.7B	$25.9B	$24.2B	$24.3B	$23.5B	$25.0B	$20.1B	$18.0B	$16.1B	$20.3B	$19.0B	$20.2B	$16.4B	$15.9B
Earnings Per Share (EPS)	$8.63	$11.03	$5.79	$13.73	$6.73	$7.81	$5.51	$5.63	$5.61	$0.47	$5.93	$5.48	$5.70	$4.81	$3.86	$3.49	$4.78	$4.40	$4.57	$3.63	$3.73
Shares Outstanding (M)	2,440M	2,429M	2,429M	2,560M	2,664M	2,674M	2,671M	2,684M	2,729M	2,745M	2,789M	2,813M	2,864M	2,877M	2,813M	2,775M	2,789M	2,789M	2,836M	2,911M	2,963M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$25.3B	$24.1B	$24.6B	$24.0B	$23.7B	$21.9B	$22.5B	$22.5B
Gross Profit	$18.5B	$17.2B	$16.6B	$16.7B	$16.1B	$14.5B	$15.4B	$15.5B
Gross Margin %	73.1%	71.5%	67.6%	69.6%	67.9%	66.4%	68.3%	69.0%
Operating Income (EBIT)	$7.2B	$6.4B	$5.6B	$7.1B	$6.8B	$6.3B	$3.8B	$5.3B
Operating Margin %	28.3%	26.6%	22.8%	29.6%	28.7%	28.8%	17.1%	23.5%
Net Income	$5.5B	$5.2B	$5.1B	$5.2B	$5.5B	$11.0B	$3.4B	$2.7B
Net Margin %	21.9%	21.8%	20.8%	21.5%	23.3%	50.2%	15.2%	12.0%
EBITDA	$7.2B	$8.3B	$7.2B	$9.3B	$8.7B	$15.6B	$5.9B	$5.4B
Earnings Per Share (EPS)	$2.27	$2.14	$2.10	$2.12	$2.29	$4.54	$1.41	$1.11
Shares Outstanding (M)	2,440M	2,445M	2,439M	2,429M	2,419M	2,424M	2,427M	2,428M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$23.7B	$24.5B	$24.3B	$22.8B	$21.2B	$23.4B	$23.5B	$23.4B	$22.2B	$21.1B	$18.8B	$19.3B	$18.5B	$17.4B	$15.4B	$14.3B	$16.4B	$16.6B	$15.0B	$15.2B	$14.2B
Capital Expenditures (CapEx)	$5.0B	$4.8B	$4.4B	$4.5B	$4.0B	$3.7B	$3.3B	$3.5B	$3.7B	$3.3B	$3.2B	$3.5B	$3.7B	$3.6B	$2.9B	$2.9B	$2.4B	$2.4B	$3.1B	$3.3B	$2.7B
Free Cash Flow (FCF)	$18.7B	$19.7B	$19.8B	$18.2B	$17.2B	$19.8B	$20.2B	$19.9B	$18.5B	$17.8B	$15.5B	$15.8B	$14.8B	$13.8B	$12.5B	$11.4B	$14.0B	$14.2B	$11.9B	$11.9B	$11.5B
FCF Margin %	19.1%	20.9%	22.3%	21.4%	21.5%	25.1%	24.4%	24.3%	22.7%	23.2%	21.6%	22.6%	19.9%	19.4%	18.5%	17.5%	22.7%	22.9%	18.7%	19.5%	21.6%
Dividends Paid	$12.6B	$12.4B	$11.8B	$11.8B	$11.7B	$11.0B	$10.5B	$9.9B	$9.5B	$8.9B	$8.6B	$8.2B	$7.8B	$7.3B	$6.6B	$6.2B	$5.8B	$5.3B	$5.0B	$4.7B	$4.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$4.7B	$2.5B	$7.3B	$9.2B	$3.9B	$4.2B	$7.0B	$8.0B
Capital Expenditures (CapEx)	$1.3B	$1.0B	$1.8B	$788M	$1.4B	$795M	$2.1B	$2.3B
Free Cash Flow (FCF)	$3.4B	$1.5B	$5.5B	$8.4B	$2.5B	$3.4B	$4.8B	$5.7B
FCF Margin %	13.4%	6.1%	22.3%	34.9%	10.4%	15.4%	21.5%	25.4%
Dividends Paid	$3.2B	$3.1B	$3.1B	$3.1B	$3.1B	$3.0B	$3.0B	$3.0B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

JNJ Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$201.1B	$199.2B	$180.1B	$167.6B	$187.4B	$182.0B	$174.9B	$157.7B	$153.0B	$157.3B	$141.2B	$133.4B	$130.4B	$132.7B	$121.3B	$113.6B	$102.9B	$94.7B	$84.9B	$81.0B	$70.6B
Cash & Cash Equivalents	$20.4B	$19.7B	$24.1B	$21.9B	$12.9B	$14.5B	$14.0B	$17.3B	$18.1B	$17.8B	$19.0B	$13.7B	$14.5B	$20.9B	$14.9B	$24.5B	$19.4B	$15.8B	$10.8B	$7.8B	$4.1B
Total Liabilities	$116.1B	$117.7B	$108.6B	$98.8B	$110.6B	$108.0B	$111.6B	$98.3B	$93.2B	$97.1B	$70.8B	$62.3B	$61.4B	$58.6B	$56.5B	$56.6B	$46.3B	$44.1B	$42.4B	$37.6B	$31.2B
Total Debt (Short + Long-Term)	$49.0B	$47.9B	$36.6B	$29.3B	$39.6B	$33.8B	$35.3B	$27.7B	$30.5B	$34.6B	$27.1B	$19.9B	$18.8B	$18.2B	$16.2B	$19.6B	$16.8B	$14.5B	$11.9B	$9.5B	$6.6B
Total Shareholders' Equity	$85.0B	$81.5B	$71.5B	$68.8B	$76.8B	$74.0B	$63.3B	$59.5B	$59.8B	$60.2B	$70.4B	$71.2B	$69.8B	$74.1B	$64.8B	$57.1B	$56.6B	$50.6B	$42.5B	$43.3B	$39.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JNJ viewer.

JNJ Metric Deep Dives

Other Companies in Pharmaceuticals

LLY · Lilly (Eli) — $1.03 trillion
MRK · Merck & Co. — $362 billion
PFE · Pfizer — $158 billion
BMY · Bristol Myers Squibb — $129 billion
ZTS · Zoetis — $30 billion
VTRS · Viatris — $19 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← JNHD All “J” companies JNK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.